Opus Genetics Stock Performance
| IRD Stock | 1.93 0.07 3.50% |
The company holds a Beta of 0.9, which implies possible diversification benefits within a given portfolio. Opus Genetics returns are very sensitive to returns on the market. As the market goes up or down, Opus Genetics is expected to follow. Opus Genetics right now holds a risk of 4.22%. Please check Opus Genetics expected short fall, and the relationship between the value at risk and daily balance of power , to decide if Opus Genetics will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Opus Genetics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Opus Genetics is not utilizing all of its potentials. The newest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Last Split Factor 1:4 | Dividend Date 2020-11-06 | Last Split Date 2020-11-06 |
1 | Opus Genetics, Inc. Sees Large Increase in Short Interest - MarketBeat | 10/31/2025 |
2 | Opus Genetics Buy Rating Reaffirmed at Chardan Capital | 11/13/2025 |
3 | Brookline Capital Markets initiates Buy rating on Opus Genetics stock - Investing.com | 12/01/2025 |
4 | Opus Genetics Upgraded to Strong-Buy at Brookline Capital Management - MarketBeat | 12/03/2025 |
5 | Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 12 Trial in Best Disease | 12/09/2025 |
6 | Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | 12/11/2025 |
7 | Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635 | 12/16/2025 |
8 | Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks | 12/19/2025 |
9 | Acquisition by Gallagher Cam of 83000 shares of Opus Genetics at 1.9689 subject to Rule 16b-3 | 12/29/2025 |
10 | Opus Genetics, Inc. Receives Average Rating of Moderate Buy from Analysts - MarketBeat | 12/30/2025 |
11 | Acquisition by Ainsworth Sean of 42507 shares of Opus Genetics at 1.99 subject to Rule 16b-3 | 12/31/2025 |
12 | Opus Genetics Cut to Sell at Wall Street Zen - MarketBeat | 01/02/2026 |
13 | Acquisition by Gallagher Cam of 67000 shares of Opus Genetics subject to Rule 16b-3 | 01/06/2026 |
14 | Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts | 01/08/2026 |
| Begin Period Cash Flow | 50.5 M | |
| Total Cashflows From Investing Activities | 1.2 M |
Opus Genetics Relative Risk vs. Return Landscape
If you would invest 200.00 in Opus Genetics on October 13, 2025 and sell it today you would lose (7.00) from holding Opus Genetics or give up 3.5% of portfolio value over 90 days. Opus Genetics is generating 0.0297% of daily returns assuming volatility of 4.2243% on return distribution over 90 days investment horizon. In other words, 37% of stocks are less volatile than Opus, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Opus Genetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opus Genetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Opus Genetics, and traders can use it to determine the average amount a Opus Genetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.007
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IRD |
Based on monthly moving average Opus Genetics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Opus Genetics by adding Opus Genetics to a well-diversified portfolio.
Opus Genetics Fundamentals Growth
Opus Stock prices reflect investors' perceptions of the future prospects and financial health of Opus Genetics, and Opus Genetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Opus Stock performance.
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (2.70) % | ||||
| Current Valuation | 103.35 M | ||||
| Shares Outstanding | 68.96 M | ||||
| Price To Book | 22.31 X | ||||
| Price To Sales | 9.10 X | ||||
| Revenue | 10.99 M | ||||
| Gross Profit | (12.79 M) | ||||
| EBITDA | (57.52 M) | ||||
| Net Income | (57.53 M) | ||||
| Total Debt | 18.84 M | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (25.58 M) | ||||
| Earnings Per Share | (1.86) X | ||||
| Market Capitalization | 133.1 M | ||||
| Total Asset | 36.86 M | ||||
| Retained Earnings | (139 M) | ||||
| Working Capital | 25.32 M | ||||
About Opus Genetics Performance
By analyzing Opus Genetics' fundamental ratios, stakeholders can gain valuable insights into Opus Genetics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Opus Genetics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Opus Genetics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.40) | (1.47) | |
| Return On Capital Employed | (2.79) | (2.65) | |
| Return On Assets | (1.40) | (1.47) | |
| Return On Equity | (9.84) | (9.35) |
Things to note about Opus Genetics performance evaluation
Checking the ongoing alerts about Opus Genetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Opus Genetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Opus Genetics may become a speculative penny stock | |
| Opus Genetics had very high historical volatility over the last 90 days | |
| Opus Genetics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 10.99 M. Reported Net Loss for the year was (57.53 M) with loss before taxes, overhead, and interest of (12.79 M). | |
| Opus Genetics generates negative cash flow from operations | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts |
- Analyzing Opus Genetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Opus Genetics' stock is overvalued or undervalued compared to its peers.
- Examining Opus Genetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Opus Genetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Opus Genetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Opus Genetics' stock. These opinions can provide insight into Opus Genetics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Opus Stock analysis
When running Opus Genetics' price analysis, check to measure Opus Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics is operating at the current time. Most of Opus Genetics' value examination focuses on studying past and present price action to predict the probability of Opus Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics' price. Additionally, you may evaluate how the addition of Opus Genetics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |